Table 3. Adjuvant therapy with hepatic arterial infusion plus newer chemotherapy agent after resection of colorectal liver metastases.
| Ref. No | Author (year) | No. of Patients | Treatment | DFS | OS |
|---|---|---|---|---|---|
| (53) | Kemeny (2003) | 96 | HAI FUDR/Dex SYS IRI |
47% 2 years | 89% 2 years |
| (54) | Kemeny (2009) | 35 | HAI FUDR/Dex SYS OXA+5-FU/LV |
88% 3 years | 88% 3 years |
| * | House (2009)a | 250 | HAI FUDR/Dex+ SYS OXA+5-FU/LV or IRI+5-FU/LV vs. SYS alone no HAI |
48% 5 years 25% 5 years |
77% 5 years 55% 5 years |
| (55) | Alberts (2010) | 76 | HAI FUDR/Dex SYS OXA+CAP |
32.7 mo | 88% 2 years |
| (56) | Kemeny (2011) | 73 | HAI FUDR/Dex SYS no Bevacizumab SYS + Bevacizumab |
46% 4 years 37% 4 years |
85% 4 years 81% 4 years |
Abbreviations: HAI, hepatic arterial infusion; FUDR, floxuridine; Dex, dexamethasone; SYS, systemic; IRI, irinotecan; mo, months; OS, overall survival; DFS, disease-free survival; OXA, oxaliplatin; 5-FU, 5-Fluorouracil; LV, leucovorin; CAP, capecitabine. *Accepted for publication in Annals of Surgery, 2011. aRetrospective; Median.